QuantLogix's current estimate for Alloy Therapeutics, published 2026-09-07 — in line with the last disclosed round of $1.0B (2026-Q2).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.0B
2026-Q2
weight 0.88
How this price has held up
No round has priced for Alloy Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Alloy Therapeutics, 2026-09-07 (391068a350ceae5c).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Alloy Therapeutics going public?
No. Alloy Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Alloy Therapeutics' valuation in 2026?
Alloy Therapeutics is valued at $1.0B as of 2026-Q2, set by its Series E ($40M, Apr 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Alloy Therapeutics filed an S-1?
No public S-1 is on file for Alloy Therapeutics.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
Waltham, MA
Employees
137
Total Raised
$173.99M
Last Round
Series E — $40M (Apr 2026)
IPO Status
private
Fundraising Status
Series E · $40M · 5 mo ago
privateTotal raised $173.99M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series E
$40M
Apr 2026
—
$1.0B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Alloy Therapeutics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-03. Re-checked weekly.
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
5
via careers page
Product-build share
40%
engineering, research, product, design
Trajectory
steady
balanced build + GTM — 40% builders vs 60% go-to-market/G&A — scaling both sides.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Oligonucleotide Design Studio[Oligonucleotide Design Studio](https://alloytx.com/oligonucleotide-design-studiSkip to contentDirector, HR Business PartnerSupport programs for family forming, new parents, menopause, and men’s health (C
Counted from Alloy Therapeutics's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyLife ScienceBiopharma
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q2. Refreshed quarterly.